Filtered By:
Specialty: Neurology
Condition: ALS

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 158 results found since Jan 2013.

The Evaluation and Management of Alternative Diagnoses in Amyotrophic Lateral Sclerosis (P5.091)
Conclusions: Treatment with intravenous steroids, immunoglobulin and surgical interventions prior to diagnosis of ALS is associated with a significantly prolonged mean ODI.Disclosure: Dr. Kannan has nothing to disclose. Dr. Glass has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kannan, M., Glass, J. Tags: Neuroepidemiology: Neuro-oncology and ALS Source Type: research

The Changing Landscape of Ethical Issues in Neurology Practice and Research (P1.365)
Conclusions: As technological advancements provide neurologists with more diagnostic and treatment options ethical considerations need to be reassessed in order to ensure adherence to medical and neurological professional codes of conduct. Many of these technological advancements have provided neurologists with tools and treatment options which although appear promising, are far from universally understood or accepted. New concerns regarding Brain death, neuro-enhancement, and TBI have emerged and merit further study.Disclosure: Dr. Bergquist has nothing to disclose. Dr. Theriault has nothing to disclose. Dr. Etienne has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Bergquist, P., Theriault, M., Etienne, M. Tags: Ethics and Policy Source Type: research

PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(R)) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study (P2.225)
Conclusion: The open-label PRISM II study supports DM/Q effectiveness for PBA irrespective of underlying etiology. Study supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Siffert has nothing to disclose. Dr. Hammond has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Abbott, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Merck, Novartis, Ortho-McNeil-Janssen, Otsuka, Pamlab, Pfizer, Shire, and Sunovion. Dr. D'Amico has received personal compensation for activities with Avanir Pharmaceuticals, Inc. Dr. Doody has receive...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Siffert, J., Hammond, F., Alexander, D., Cutler, A., D'Amico, S., Doody, R., Sauve, W., Zorowitz, R., Davis, C., Shin, P., Ledon, F., Yonan, C., Formella, A. Tags: Aging and Dementia: Therapeutics Source Type: research

Proteostasis impairment in ALS.
Abstract In physiological conditions the maintenance of the cellular proteome is a prerequisite for optimal cell functioning and cell survival. Additionally, cells need to constantly sense and adapt to their changing environment and associated stressors. Cells achieve this via a set of molecular chaperones, protein clearance pathways as well as stress-associated signaling networks which work together to prevent protein misfolding, its aggregation and accumulation in subcellular compartments. These processes together form the proteostasis network which helps in maintaining cellular proteostasis. Imbalance or impair...
Source: Brain Research - March 27, 2016 Category: Neurology Authors: Ruegsegger C, Saxena S Tags: Brain Res Source Type: research

Evidence for the Importance of Vitamin D Status in Neurologic Conditions
Opinion statement Vitamin D status has been proposed as relevant to many neurological disorders. Data suggest that vitamin D may be important for the development of the nervous system, and it also plays a role in neuroimmunology and neuroprotection. Lower levels of circulating 25-hydroxyvitamin D have been linked with increased risk of multiple sclerosis (MS) and Alzheimer’s disease (AD). While people with amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and stroke have lower vitamin D levels than those without the diseases, it is unclear if this is because hypovitaminosis D contributes to disea...
Source: Current Treatment Options in Neurology - November 4, 2015 Category: Neurology Source Type: research

Nuclear transport problems linked to ALS and FTD
Three teams of scientists supported by the National Institutes of Health showed that a genetic mutation linked to some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) may destroy neurons by disrupting the movement of materials in and out of the cell’s nucleus, or command center where most of its DNA is stored.
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - October 16, 2015 Category: Neurology Source Type: news

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
CONCLUSIONS: DM/Q significantly reduced PBA symptoms in patients with dementia; reported adverse events were consistent with the known safety profile of DM/Q. Trial Registration clinicaltrials.gov identifier: NCT01799941. PMID: 26471212 [PubMed - as supplied by publisher]
Source: CNS Spectrums - October 16, 2015 Category: Neurology Authors: Doody RS, D'Amico S, Cutler AJ, Davis CS, Shin P, Ledon F, Yonan C, Siffert J Tags: CNS Spectr Source Type: research

Association of Pseudobulbar Affect Symptoms with Quality of Life and Healthcare Costs in Veterans with Traumatic Brain Injury
Pseudobulbar affect (PBA) is an affect disinhibition syndrome characterized by uncontrollable, exaggerated, and often inappropriate outbursts of crying or laughing.(Schiffer and Pope, 2005) It has been associated with disruption or damage to neural systems that modulate voluntary and involuntary emotional expression(Wortzel et al., 2008, Parvizi et al., 2009, Lauterbach et al., 2013)PBA has been identified in patients with a multitude of neurological disorders, including traumatic brain injury (TBI), amyotrophic lateral sclerosis, multiple sclerosis, stroke, and Alzheimer's disease.(Moore et al., 1997, Schiffer and Pope, 2...
Source: Journal of Affective Disorders - October 15, 2015 Category: Neurology Authors: James L. Rudolph, Jennifer R. Fonda, Phillip R. Hunt, Regina E. McGlinchey, William P. Milberg, Matthew W. Reynolds, Charles Yonan Source Type: research

Dormant viral genes may awaken to cause ALS
Scientists at the National Institutes of Health (NIH) discovered that reactivation of ancient viral genes embedded in the human genome may cause the destruction of neurons in some forms of amyotrophic lateral sclerosis (ALS).
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - September 30, 2015 Category: Neurology Source Type: news

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
Abstract Cannabinoids form a singular family of plant-derived compounds (phytocannabinoids), endogenous signaling lipids (endocannabinoids), and synthetic derivatives with multiple biological effects and therapeutic applications in the central and peripheral nervous systems. One of these properties is the regulation of neuronal homeostasis and survival, which is the result of the combination of a myriad of effects addressed to preserve, rescue, repair, and/or replace neurons, and also glial cells against multiple insults that may potentially damage these cells. These effects are facilitated by the location of spec...
Source: Neurotherapeutics - August 11, 2015 Category: Neurology Source Type: research

Regenerative cellular Therapies for neurologic Diseases.
Abstract The promise of stem cell regeneration has been the hope of many neurologic patients with permanent damage to the central nervous system. There are hundreds of stem cell trials worldwide intending to test the regenerative capacity of stem cells in various neurological conditions from Parkinson's disease to multiple sclerosis. Although no stem cell therapy is clinically approved for use in any human disease indication, patients are seeking out trials and asking clinicians for guidance. This review summarizes the current state of regenerative stem cell transplantation divided into seven conditions for which ...
Source: Brain Research - July 31, 2015 Category: Neurology Authors: Levy M, Boulis N, Rao M, Svendsen CN Tags: Brain Res Source Type: research

Risks of Epilepsy During Pregnancy
Epilepsy is a common disease that affects 1 in 26 individuals in their lifetime. According to a National Institute of Neurological Disorders and Stroke assessment, with 2 million affected individuals, epilepsy ranks only fourth to migraine, stroke, and Alzheimer disease in the prevalence of neurological disorders. Epilepsy affects more people than autism, amyotrophic lateral sclerosis, cerebral palsy, multiple sclerosis, and Parkinson disease combined. Approximately 0.3% to 0.5% of all pregnancies are among women with epilepsy (WWE). The risks during pregnancy in WWE have been uncertain.
Source: JAMA Neurology - July 6, 2015 Category: Neurology Source Type: research

Current approaches to enhance glutamate transporter function and expression
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - June 20, 2015 Category: Neurology Authors: Andréia C. K. Fontana Tags: Review Source Type: research

Scientists create mice with a major genetic cause of ALS and FTD
Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), both of which are caused by a mutation in the a gene called C9ORF72.
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - May 22, 2015 Category: Neurology Source Type: news

Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders
Abstract Extracellular vesicles (EVs), including exosomes, microvesicles and apoptotic bodies, participate in intercellular communication, and particularly, in paracrine and endocrine signalling. The EVs and their specific contents have been considered hallmarks of different diseases. It has been recently discovered that EVs can co-transport nucleic acids such as DNAs, ribosomal RNAs, circular RNAs (circRNAs), long noncoding RNAs (lnRNAs) and microRNAs (miRNAs). miRNAs are important regulators of gene expression at the post-transcriptional level, although they may also play other roles. Recent evidence supports th...
Source: Molecular Neurobiology - April 11, 2015 Category: Neurology Source Type: research